Home Medizin Neuester COVID-19-Booster halbiert das Risiko einer mittelschweren oder schweren Erkrankung bei Erwachsenen

Neuester COVID-19-Booster halbiert das Risiko einer mittelschweren oder schweren Erkrankung bei Erwachsenen

von NFI Redaktion

According to a new nationwide data study from September 2023 to January 2024, a period of JN.1 variant dominance, the latest COVID-19 booster shot reduces the risk of moderate to severe COVID-19 infection in adults by over half.

This new study is one of the first to evaluate the protection provided by the updated COVID-19 vaccination against COVID-19-related emergency room and critical care visits (a marker of moderate illness) as well as hospitalizations (a marker of severe illness) in individuals aged 18 and over, due to JN.1, the most recently predominant COVID strain.

Halving your risk of needing to visit an emergency room or critical care center or being hospitalized due to COVID is significant. As a data scientist, I want to emphasize that the data we analyzed comes from various populations and geographic locations, adults of all ages, and the latest COVID strain. This analysis clearly underlines the benefits of a booster shot, and as a clinician, I encourage my patients to get one.“


Shaun Grannis, MD, MS, Co-author of the study, Vice President of the Regenstrief Institute for Data and Analytics and Professor at the Indiana University School of Medicine

„These are encouraging results,“ said study co-author Brian Dixon, PhD, MPA, Interim Director of the Clem McDonald Center for Biomedical Informatics at the Regenstrief Institute and Professor at the Richard M. Fairbanks School of Public Health at Indiana University. „These vaccine effectiveness estimates align with what we would expect from an annual booster shot developed against an endemic virus that is constantly evolving. We have looked at a longer timeframe than similar studies in Europe and found good performance. However, we must caution about the potential waning of effectiveness of the updated booster shot, as seen with previous COVID-19 vaccines. Americans should expect that the CDC will recommend future booster shots, likely on an annual basis.“

These findings on protection against moderate and severe illness from the booster shot in this large study are consistent with those from an earlier, smaller study involving individuals tested at a pharmacy, which did not include hospital patients.

The authors of the new study, Dr. Grannis and Dixon, concluded: „In this analysis of updated COVID-19 VE [vaccine effectiveness], receiving an updated COVID-19 vaccine dose provided protection against COVID-19-associated emergency department/critical care visits and hospitalizations in immunocompetent adults. The CDC will continue to monitor the VE of updated COVID-19 vaccines. All adults should stay updated on the recommended COVID-19 vaccines and receive a dose of the updated vaccine.“

Source:

Journal Reference:

DeCuir, J., et al. (2024) Preliminary effectiveness of updated COVID-19 vaccines 2023–2024 (monovalent January 2024. Morbidity and Mortality Weekly Report (MMWR). doi.org/10.15585/mmwr.mm7308a5.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.